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Summary 
Background: Alanine-aminotransferase (ALT) and uric acid
cut-off levels used in non-alcoholic fatty liver disease
(NAFLD) diagnosis are advised to be lowered. Due to
contradictory results on the utility of both these biomarkers
for NAFLD screening, we aimed to determine their cut-off
levels that can be applied to Montenegrin population with
the fatty liver disease.
Methods: A total of 771 volunteers were enrolled. A fatty
liver index (FLI) score ≥60 was used as proxy of NAFLD.
The receiver operating characteristic curve analysis with the
area under the curve (AUC) was used to determine the cut-
off values of ALT and uric acid associated with FLI ≥60.
Results: ALT was independent predictor of FLI in both men
and women, whereas serum uric acid was its independent
predictor only in women. Lower cut-off levels of ALT are
associated with the increased prevalence of NAFLD [i.e.,
ALT was 19 IU/L (AUC=0.746, sensitivity 63%, specificity
72%, P<0.001) in women and 22 IU/L (AUC=0.804,
sensitivity 61%, specificity 95%, P<0.001) in men]. The
cut-off value for uric acid was 274 mmol/L (AUC=0.821,
sensitivity 68%, specificity 82%, P<0.001) in women. 
Conclusions: Lower cut-off levels of ALT in both genders,
and serum uric acid in females, can be reliable predictors of
the FLI.
Keywords: fatty liver, hyperuricemia, inflammation,
transaminases, obesity
Kratak sadr`aj
Uvod: Preporuka skorijih studija je da cut-off vrednosti
alanin-aminotransferaze (ALT) i mokra}ne kiseline budu
ni`e u cilju dijagnostikovanja nealkoholne steatoze jetre. S
obzirom na postojanje opre~nih rezultata kada su u pitanju
ovi biomarkeri u cilju skrininga na nealkoholnu steatozu
jetre, cilj ove studije je bio da se odrede cut-off vrednosti
koje bi mogle biti primenjive u crnogorskoj populaciji za
dijagnostiku ovog poreme}aja.
Metode: Istra`ivanje je obuhvatilo ukupno 771 dobrovoljca.
Indeks masne jetre (engl. fatty liver index-FLI) ≥60 je
kori{ten za dijagnostikovanje nealkoholne steatoze jetre.
ROC analiza i povr{ina ispod krive (engl. area under the
curve-AUC) su kori{teni za odre|ivanje cut-off vrednosti
ALT i mokra}ne kiseline, koji su povezani sa FLI ≥60.
Rezultati: ALT je nezavisan prediktor FLI kod oba pola, dok
je mokra}na kiselina nezavisan prediktor masne jetre samo
kod `ena. Tako|e, ni`e cut-off vrednosti ALT su povezane
sa ve}om prevalencom pojave masne jetre [za ALT kod
`ena vrednost je 19 IU/L (AUC=0,746, senzitivnost 63%,
specifi~nost 72%, P<0,001), a kod mu{karaca je 22 IU/L
(AUC=0,804, senzitivnost 61%, specifi~nost 95%, P<0,001)].
Cut-off vrednost za mokra}nu kiselinu za pojavu masne
jetre kod `ena je 274 mmol/L (AUC=0,821, senzitivnost
68%, specifi~nost 82%, P<0,001).
Zaklju~ak: Ni`e cut-off vrednosti ALT kod oba pola, kao i
ni`e vrednosti mokra}ne kiseline kod `ena, mogu biti
pouzdani prediktori za pojavu masne jetre. 
Klju~ne re~i: masna jetra, hiperurikemija, inflamacija,
transaminaze, gojaznost
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Introduction
It is widely recognized that non-alcoholic fatty
liver disease (NAFLD) represents the commonest
mani festation of chronic liver diseases (1). Its pre -
valence is rising along with the growing proportion of
obesity and diabetes mellitus type 2 (DM2) worldwide.
Although it looks like a benign condition, without any
symptoms, during a certain time NAFLD increases the
risk of cirrhosis and hepatocellular carcinoma
(1). Importantly, it is an early predictor of diabetic
complications and cardiovascular disease (CVD) (2, 3). 
Liver biopsy is established as the gold standard
for diagnosis of hepatic steatosis (4). However, due to
its invasive diagnostic nature it is not suitable
procedure in routine everyday praxis. Therefore, it
has been replaced with abdominal ultrasonography,
as the commonest technique for NAFLD assessment
in clinical trials. In line with this, Bedogni et al. (5)
derived fatty liver index (FLI), an algorithm based on
body mass index (BMI), waist circumference (WC),
triglycerides (TG) and gamma-glutamyl transferase
(GGT), as a simple and accurate predictor of NAFLD.
An FLI score ≥60 has been shown to have good
sensitivity and specificity for NAFLD when diagnosed
by abdominal ultrasonography, thus making it
suitable for assessment hepatic steatosis in general
population (5, 6).
Alanine-aminotransferase (ALT) (7, 8), and uric
acid (9, 10), are shown to be independently
associated with NAFLD. On the other hand, some
studies advised that the ALT cut-off level used in
NAFLD diagnosis should be revised and lowered (11,
12), since a threshold of 40 IU/L is commonly used
in clinical practice (12). However, even with lower cut-
off levels, ALT was shown to be a poor marker of
NAFLD in some studies (8, 12, 13).
Similarly, discrepant results were observed when
examining uric acid in relation to NAFLD, especially
focusing on sex-specific differences and obesity status
(14–17).
To our knowledge, there are no data on the
prevalence of fatty liver in general population in Monte -
negro. Considering the high prevalence of over -
weight/obesity (18) and DM2 (19) in Monte negro, the
early diagnosis of NAFLD is of great importance. Due
to discrepant results on the utility of both these
biomarkers for NAFLD screening, we aimed to
determine their cut-off levels that can be applied to
Montenegrin population with fatty liver disease.
Materials and Methods
Study population
Out of the total number of 1000 participants
(397 men and 603 women) who were screened, 771
of them met the inclusion criteria in the current cross-
sectional study (249 men and 522 women). Parti -
cipants were sequentially recruited in the Primary
Health Care Centre in Podgorica, Montenegro, during
their routine check-up in a period from October 2012
to May 2016. Subjects older than 18 years of age were
included in the study. Participants were regarded to
have DM2 if they exibited HbA1c ≥ 6.5% measured
on two different occasions, or with at least two
measurements of fasting glucose levels ≥ 7.0 mmol/L,
or with a random plasma glucose level of ≥ 11.1
mmol/L, or a plasma glucose level ≥ 11.1 mmol/L 2
h after an oral glucose tolerance test. Also, participants
were regarded to have DM2 if they self-reported DM2,
as well as if they were treated with oral hypoglycemic
agents or insulin, as described else where (20).
Participants were excluded from the research if
they had liver disease other than NAFLD, malignant
diseases, renal dysfunction, cardiovascular diseases,
ethanol consumption >20 g/day, type 1 diabetes
mellitus, high sensitivity C-reactive protein levels
(hsCRP) > 10 mg/L, younger than 18 years of age,
pregnancy.
Written informed consent was provided by each
participant and all procedures performed in the
current research were in accordance with the
standards of the Ethical Committee of Primary Health
Care Centre in Podgorica, Montenegro and with the
Declaration of Helsinki.
Anthropometric and blood pressure
measurements
Basic anthropometric measurements, systolic
blood pressure (SBP) and diastolic blood pressure
(DBP) were measured as described previously (21).
Biochemical analyses
The blood samples were taken in the morning,
between 7 and 10 o’clock, after at least 8 hours of
fasting. Serum levels of glucose, total cholesterol,
high density lipoprotein cholesterol (HDL-c), low density
lipoprotein cholesterol (LDL-c), TG, creatinine, uric
acid, total bilirubin, aspartate aminotransferase (AST),
ALT and GGT, were measured using standardized
enzymatic procedures, spectrophotometrically (Roche
Cobas 400, Mannheim, Germany). Serum hsCRP
levels were determined using a nephelometric assay
(Behring Nephelometer Analyzer, Marburg, Germany). 
Assessment of non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease is assessed by
FLI, using the following algorithm (5): 
FLI = (e0.953 × loge (triglycerides) + 0.139 × BMI + 0.718 × loge
(GGT) + 0.053 × waist circumference − 15.745)/ (1 + e0.953 × loge
(triglycerides) + 0.139 × BMI + 0.718 × loge (GGT) + 0.053 × waist
circumference − 15.745) × 100.
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A FLI score ≥60 has been shown to have good
sensitivity and specificity, thus making it a convenient
proxy of NAFLD. The 2016 EASL-EASD-EASO NAFLD
guidelines are based on the recommendations on the
usage of the serum biomarkers as endorsed
diagnostic tool with the FLI as one of the best
validated steatosis scores for screening studies in
large population samples (22).
Statistical analysis
The parameter distribution was tested by the
Kolmogorov Smirnov test and the data were pre -
sented as median (interquartile range). Categorical
data were presented as relative frequencies and
compared by Chi-square test for contingency tables.
Kruskal-Wallis test was employed for comparisons
between three groups of patients based on FLI
separately in men and women. Correlations between
FLI and clinical parameters were tested by Spear -
man’s correlation analysis. Multivariate logistic
regression analysis was used to find models consisting
of clinical parameters (predictors, independent
variables) which significantly influence the variability
in the FLI, as dependent variable. The group of
patients with FLI <30 was coded as 0, while the
group of patients with FLI ≥60 was coded as 1.
Variables in the FLI equation (i.e. BMI, WC, TG and
GGT) were excluded from multivariate analyses.
Results are presented by odds ratio (OR) with 95%
confidence intervals (CI). The explained variation in
FLI was given by Nagelkerke R2 value for single
predictors and models. The Hosmer and Lemeshow
test was used to examine whether there was a linear
relationship between the independent variables and
the log odds of the dependent variable. The clinical
accuracy of the examined parameters and models
were assessed by using receiver operating chara -
 cteristic (ROC) curve analysis. The same analysis was
also used to determine the cut-off values of the ALT
and uric acid associated with the increase in the
prevalence of the fatty liver disease (i.e., FLI ≥60) in
both genders. The area under the ROC curve (AUC)
between 0.5 and 0.7 suggested the low accuracy of
diagnostic test; between 0.7 and 0.8 satisfactory
accuracy, between 0.8 and 0.9 good accuracy, while
AUC higher than 0.9 suggested the excellent
accuracy of diagnostic test (23). Statistical analyses
were performed with IBM® SPSS® Statistics version
22 software (USA). In all the analyses, values were
considered statistically significant at P < 0.05.
Results
Table I indicates the general characteristics of
men according to FLI. As expected, all three FLI
Table I General clinical data of study men’s population according to FLI.
Data are presented as median (interquartile range) and compared by Kruskal–Wallis with post hoc test. 
a – significantly different from the first FLI group, p<0.05
b – significantly different from the second FLI group, p<0.05
BMI – Body mass index; WC – Waist circumference; SBP – Systolic blood pressure; DBP – Diastolic blood pressure
First FLI group
(FLI<30)
Second FLI group 
(FLI ≥30, <60)
Third FLI group 
(FLI ≥60) P
N 28 66 155

























Smokers, n (%) 5 (18%) 20 (30%) 41 (26%) 0.800
Antihyperglycemics, n (%) 11 (39%) 28 (42%) 89 (57%) 0.065
Insulin, n (%) 5 (18%) 10 (15%) 28 (18%) 0.643
Antihyperlipidemics, n (%) 11 (39%) 16 (24%) 65 (42%) 0.012
Antihypertensives, n (%) 13 (46%) 41 (62%) 111 (72%) 0.141
Type 2 diabetes mellitus, n (%) 14 (50%) 30 (45%) 100 (64%) 0.011
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Table II General clinical data of study women’s population according to FLI.
Table III Biochemical analysis of study men’s population according to FLI.
First FLI group 
(FLI <30)
Second FLI group 
(FLI ≥30, <60)
Third FLI group 
(FLI ≥60) P
N 186 137 199 <0.001
Age, years 56.00 (49.00–61.00) 60.00 (55.00–67.00)a 62.00 (56.00–68.00)a <0.001
BMI, kg/m2 23.59 (21.50–25.07) 27.78 (26.13–29.40)a 32.24 (30.18–35.54)a,b <0.001
WC, cm 82.00 (77.00–88.00) 95.00 (92.00–99.00)a 107.00 (100.00–112.00)a,b <0.001
SBP, mmHg 129.00 (115.00–140.00) 136.00 (127.00–147.00)a 135.00 (126.00–146.00)a <0.001
DBP, mmHg 78.00 (70.00–90.00) 85.00 (76.00–94.00)a 81.00 (76.00–90.00)a 0.001
Smokers, n (%) 27 (15%) 19 (14%) 25 (13%) 0.800
Antihyperglycemics, 
n (%) 9 (5%) 28 (20%) 87 (44%) <0.001
Insulin, n (%) 2 (1%) 7 (5%) 14 (7%) 0.016
Antihyperlipidemics, 
n (%) 22 (12%) 27 (20%) 66 (33%) <0.001
Antihypertensives, 
n (%) 38 (20%) 56 (41%) 134 (67%) <0.001
Type 2 diabetes
mellitus, n (%) 10 (5%) 30 (22%) 101 (51%) <0.001
Data are presented as median (interquartile range) and compared by Kruskal–Wallis with post hoc test. 
a – significantly different from the first FLI group, p<0.05; b – significantly different from the second FLI group, p<0.05
HDL-c-High density lipoprotein cholesterol; LDL-c-Low density lipoprotein cholesterol; TG – Triglycerides; AST – Aspartate aminotransferase; ALT
– Alanine aminotransferase; GGT – Gamma-glutamyl transferase; HsCRP – High-sensitivity C-reactive protein; FLI – Fatty liver index
First FLI group 
(FLI<30)
Second FLI group 
(FLI ≥30, <60)
Third FLI group 
(FLI 60) P
Glucose, mmol/L 5.90 (5.50–6.30) 6.10 (5.40–7.40) 6.70 (5.60–8.67)a,b 0.008
Total cholesterol, mmol/L 4.44 (4.12–5.29) 5.09 (4.60–5.78)a 5.22 (4.57–6.02)a 0.020
HDL–c, mmol/L 1.52 (1.16–1.71) 1.27 (1.03–1.61) 1.01 (0.88–1.26)a,b <0.001
LDL–c, mmol/L 2.82 (1.82–3.39) 2.96 (2.68–3.88) 3.20 (2.49–3.83) 0.055
TG, mmol/L 1.00 (0.84–1.26) 1.48 (1.03–1.80)a 2.08 (1.66–2.73)a,b <0.001
AST, IU/L 18.00 (16.00–21.00) 21.00 (18.00–24.00)a 20.00 (18.00–25.00)a,b 0.219
ALT, IU/L 16.50 (14.00–20.00) 22.00 (18.00–28.00)a 24.00 (17.00–30.00)a,b <0.001
GGT, IU/L 13.00 (11.00–17.00) 18.00 (14.00–25.00)a 27.00 (20.00–37.00)a,b <0.001
Uric acid, mmol/L 313.00 (250.00–366.00) 300.00 (262.00–364.00) 333.00 (283.00–382.00) 0.084
Total bilirubin, mmol/L 9.25 (5.50–12.70) 8.70 (6.40–11.84) 8.60 (5.95–12.07) 0.978
HsCRP, mg/L 0.73 (0.38–1.58) 0.83 (0.48–1.66) 1.53 (0.84–3.27)a,b <0.001
Creatinine, mmol/L 86.00 (80.00–94.00) 83.00 (75.00–96.00) 84.00 (74.00–97.00) 0.823
FLI 22.00 (15.00–26.00) 48.00 (40.00–54.00)a 85.00 (73.00–92.00)a,b <0.001
Data are presented as median (interquartile range) and compared by Kruskal-Wallis with post hoc test. 
a – significantly different from the first FLI group, p<0.05; b – significantly different from the second FLI group, p<0.05
BMI – Body mass index; WC – Waist circumference; SBP – Systolic blood pressure; DBP – Diastolic blood pressure
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Table IV Biochemical analysis of study women’s population according to FLI.
Data are presented as median (interquartile range) and compared by Kruskal-Wallis with post hoc test. 
a – significantly different from the first FLI group, p<0.05; b – significantly different from the second FLI group, p<0.05
HDL-c-High density lipoprotein cholesterol; LDL-c-Low density lipoprotein cholesterol; TG – Triglycerides; AST – Aspartate aminotransferase;
ALT – Alanine aminotransferase; GGT – Gamma-glutamyl transferase; HsCRP – High-sensitivity C-reactive protein; FLI – Fatty liver index
First FLI group 
(FLI<30)
Second FLI group 
(FLI ≥30, <60)
Third FLI group 
(FLI ≥60) P
Glucose, mmol/L 5.30 (5.00–5.70) 5.60 (5.10–6.20)a 6.50 (5.60–7.70)a,b <0.001
Total cholesterol, mmol/L 5.80 (4.96–6.66) 6.02 (5.25–6.71) 6.13 (5.20–7.06)a 0.022
HDL–c, mmol/L 1.76 (1.48–2.02) 1.56 (1.28–1.75)a 1.27 (1.10–1.45)a, b <0.001
LDL–c, mmol/L 3.51 (2.83–4.20) 3.74 (2.96–4.41) 3.86 (2.96–4.72) a 0.039
TG, mmol/L 1.11 (0.85–1.41) 1.43 (1.03–2.01)a 2.27 (1.73–2.91)a,b <0.001
AST, IU/L 18.00 (15.00–21.00) 18.00 (16.00–21.00) 19.00 (17.00–24.00)a,b <0.001
ALT, IU/L 15.00 (12.00–20.00) 19.00 (14.00–23.00)a 22.00 (17.00–30.00)a,b <0.001
GGT, IU/L 10.00 (9.00–13.00) 14.00 (11.00–17.00)a 19.00 (14.00–25.00)a,b <0.001
Uric acid, mmol/L 220.00 (191.00–261.00) 256.00 (225.00–298.00)a 316.00 (254.00–355.00)a,b <0.001
Total bilirubin, mmol/L 7.50 (5.70–9.80) 7.10 (5.80–9.80)a 6.60 (5.10–8.60)a 0.011
HsCRP, mg/L 0.52 (0.30–1.15) 1.36 (0.89–2.40)a 2.16 (1.16–4.24)a,b <0.001
Creatinine, mmol/L 58.00 (53.00–64.00) 63.00 (57.00–71.00)a 65.00 (58.00–73.00)a,b <0.001
FLI 12.00 (7.00–21.00) 42.00 (37.00–49.00)a 83.00 (69.00–91.00)a,b <0.001
Table V Spearman’s correlation coefficients of FLI and other clinical parameters in men and women.
Data are presented as correlation coefficient Rho (r)
BMI – Body mass index; WC – Waist circumference; SBP – Systolic blood pressure; DBP – Diastolic blood pressure; HDL-c – High density
lipoprotein cholesterol; LDL-c – Low density lipoprotein cholesterol; TG –Triglycerides; AST – Aspartate aminotransferase; ALT – Alanine
aminotransferase; GGT – Gamma-glutamyl transferase; HsCRP – High-sensitivity C-reactive protein
Men Women
Variable r P r P
Age, years 0.165 0.009 0.315 <0.001
BMI, kg/m2 0.839 <0.001 0.894 <0.001
WC, cm 0.815 <0.001 0.904 <0.001
SBP, mmHg 0.097 0.131 0.243 <0.001
DBP, mmHg 0.030 0.643 0.148 0.001
Glucose, mmol/L 0.194 0.002 0.547 <0.001
Total cholesterol, mmol/L 0.112 0.080 0.101 0.022
HDL-c, mmol/L -0.397 <0.001 -0.562 <0.001
LDL-c, mmol/L 0.071 0.267 0.089 0.042
TG, mmol/L 0.593 <0.001 0.654 <0.001
AST, IU/L 0.120 0.060 0.165 <0.001
ALT, IU/L 0.322 <0.001 0.395 <0.001
GGT, IU/L 0.564 <0.001 0.580 <0.001
Uric acid, mmol/L 0.186 0.003 0.529 <0.001
Total bilirubin, mmol/L -0.041 0.522 -0.146 0.001
HsCRP, mg/L 0.347 <0.001 0.571 <0.001
Creatinine, mmol/L -0.027 0.676 0.291 <0.001
groups had significantly different BMI and WC
because those variables were used for FLI calculation.
The second and the third FLI group had significantly
higher SBP and DBP than the first FLI group. Also,
the third FLI group had significantly higher
percentage of subjects on antihyperlipidemic therapy.
The same percentages of men with DM2 were
included in the first and in the third group, and both
being higher than those in the second FLI group.
It was evident in Table II that significantly higher
percentage of women on antihyperglycemic, insulin,
antihyperlipidemic and antihypertensive therapies and
women with DM2 were in the third FLI group (i.e.,
group with fatty liver disease). Women in the second
and in the third FLI group were older and had
significantly higher DBP than women in the first
group. Furthermore, BMI, WC and SBP were
significantly different between all three groups, being
higher in the second and the third group than in the
first one.
Beside TG concentration and GGT, ALT activity
was different between all men’s FLI groups, being the
highest in men with fatty liver disease (i.e., FLI ≥60).
Also, HDL-c was the lowest in men with fatty liver
disease (i.e., FLI ≥60). Vice versa was established for
hsCRP levels, which were the highest in men with FLI
≥60. Total cholesterol concentration was the lowest
in men without fatty liver disease (i.e., FLI<30),
(Table III).
As in men, TG concentration and GGT activity,
were significantly different between all three FLI
groups, being the highest in women with fatty liver.
The same was found for glucose, HDL-c, uric acid,
hsCRP, creatinine concentrations and ALT activity.
Total cholesterol and LDL-c were higher in women
with fatty liver disease than in those who did not have
it. Total bilirubin concentration was the highest in
women without fatty liver (i.e., FLI <30) and AST
activity was the highest in women with fatty liver (i.e.,
FLI ≥60), (Table IV). 
Bivariate associations were revealed by Spear -
man’s correlation analysis. In men, FLI was highly
asso ciated with all the parameters used for its
calculation (BMI, WC, TG and GGT). Also, significant
positive associations were established between FLI
and age, glucose, ALT, uric acid, hsCRP and signifi -
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Table VI Odds ratios (OR) after univariate and multivariate logistic regression analysis for ALT and UA predicting abilities towards







ALT, IU/L 1.178 (1.079–1.287) <0.001 0.247
Uric acid, mmol/L 1.004 (0.998–1.010) 0.170 0.021
Model 1 AdjustedOR (95%CI) P
Nagelkerke 
R2
ALT, IU/L 1.313 (1.135–1.518) <0.001 0.554







ALT, IU/L 1.126 (1.090–1.162) 0.001 0.253
Uric acid, mmol/L 1.020 (1.015–1.029) <0.001 0.383
Model 2 AdjustedOR (95%CI) P
Nagelkerke 
R2
ALT, IU/L 1.167 (1.080–1.261) <0.001 0.797
Model 3
Uric acid, mmol/L 1.014 (1.007–1.021) <0.001 0.791
Model 4
ALT, IU/L 1.170 (1.078–1.270) <0.001 0.818
Uric acid, mmol/L 1.014 (1.006–1.022) <0.001
Model 1: Age, Glucose, HDL-c, uric acid, hsCRP, ALT (all continuous variables) and antihyperlipemics and type 2 diabetes mellitus (all categorical
variables)
Model 2: Age, Glucose, total cholesterol, HDL-c, LDL-c, ALT, creatinine, hsCRP, SBP, DBP, AST, total bilirubin (all continuous variables) and gender,
antihyperglycemics, insulin, antihyperlipidemics, antihypertensives, type 2 diabetes mellitus (all categorical variables)
Model 3: Age, Glucose, total cholesterol, HDL-c, LDL-c, uric acid, creatinine, hsCRP, SBP, DBP, AST, total bilirubin (all continuous variables) and
gender, antihyperglycemics, insulin, antihyperlipidemics, antihypertensives, type 2 diabetes mellitus (all categorical variables)
Model 4: Age, Glucose, total cholesterol, HDL-c, LDL-c, ALT, uric acid, creatinine, hsCRP, SBP, DBP, AST, total bilirubin (all continuous variables)
and gender, antihyperglycemics, insulin, antihyperlipidemics, antihypertensives, type 2 diabetes mellitus (all categorical variables)
cant negative association between FLI and HDL-c. In
women, FLI correlated positively with all the
examined parameters, except with HDL-c and total
bilirubin. FLI correlated highly negatively with HDL-c
and total bilirubin. Correlation coefficients (r) and P
values were presented in Table V.
Further statistical analysis included binary
logistic regression in order to determine whether
measurement of ALT and uric acid which significantly
correlated with FLI could have a potential predictive
role on fatty liver occurrence. The first FLI group (FLI
<30) was selected as a reference group and coded as
0 while the third FLI group (FLI ≥60) was selected as
group of patients with fatty liver disease and coded as
1. Coding was performed separately in men and
women. Unadjusted analysis indicated that in men
ALT was a predictor and in women ALT and uric acid
were predictors for fatty liver disease. As ALT activity
rose for 1 IU/L, probability for fatty liver disease
increased by 17.8% in men (Table VI). The un -
adjusted Nagelkerke R2 for FLI of 0.247 means that
24.7% of variation in FLI was caused by ALT in men.
As ALT activity rose for 1 IU/L and uric acid con -
centration rose for 1 mmol/L, probability for fatty liver
disease in women increased by 12.6% and 2%,
respectively (Table VI). In women, the unadjusted
Nagelkerke R2 for FLI of 0.253 and 0.383 means
that 25.3% and 38.3% of variations in FLI were
caused by ALT and uric acid, respectively. 
Thereafter, we constructed logistic regression
models to further test the potential independent
associations of the ALT and uric acid with fatty liver
disease in men and women. The best models for each
of the investigated clinical parameter are presented in
Table VI. In men the Model 1 incorporated adjust -
ments for all the clinical parameters significantly
correlated with FLI as continuous variables, and
therapy usage and DM2 presence differently
distributed among FLI groups as categorical variables.
In women models 2, 3 and 4 incorporated adjust -
ments for all the clinical parameters significantly
correlated with FLI as continuous variables and
therapy usages and DM2 presence differently
distributed among FLI groups as categorical variables.
ALT kept its independent predictive power on fatty
liver disease in men [OR (95% CI) = 1.313 (1.135–
1.518), P < 0.001]. The level of influence of the
Model 1 on variation of FLI was 55.4% (Table VI).
Also, ALT kept its independent prediction in Model 2
and Model 4 on fatty liver disease in women: [OR
(95% CI) = 1.167 (1.080–1.261), P <0.001] and
[OR (95% CI) = 1.170 (1.078–1.270), P <0.001],
respectively. Uric acid was independent predictor of
fatty liver disease only in women: the Model 3 [OR
(95% CI) = 1.014 (1.007–1.021), P <0.001] and
the Model 4 [OR (95% CI) = 1.014 (1.006–1.022),
P < 0.001]. The levels of influence of the Models 2,
3 and 4 on variation of FLI were 79.9%, 79.1% and
81.8%, respectively.
Furthermore, we performed the ROC analysis in
order to test the clinical accuracy of ALT in men and
ALT and uric acid in women towards the presence of
fatty liver disease (Table VII). The calculated AUC for
ALT as a single parameter indicated its good clinical
accuracy (23): AUC (95% CI) = 0.804 (0.719–
0.890), P <0.001 in development of fatty liver
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Table VII ROC analysis for single parameter discriminatory abilities towards fatty liver disease development in men and women.
Predictors AUC(95% CI) SE Sensitivity (%) Specificity (%) P
Men
ALT, IU/L 0.804 (0.719–0.890) 0.044 61 95 <0.001
Uric acid, mmol/L 0.576 (0.500–0.650) 0.067 74 46 >0.05
Model 1 0.932 (0.891–0.974) 0.021 74 100 0.001
Women
ALT, IU/L 0.746 (0.698–0.794) 0.025 63 72 <0.001
Uric acid, mmol/L 0.820 (0.779–0.858) 0.021 65 84 <0.001
Model 2 0.965 (0.948–0.982) 0.009 90 91 <0.001
Model 3 0.965 (0.948–0.982) 0.009 88 92 <0.001
Model 4 0.971 (0.956–0.986) 0.008 92 90 <0.001
Model 1: Age, Glucose, HDL-c, uric acid, hsCRP, ALT (all continuous variables) and antihyperlipidemics and type 2 diabetes mellitus (all
categorical variables)
Model 2: Age, Glucose, total cholesterol, HDL-c, LDL-c, ALT, creatinine, hsCRP, SBP, DBP, AST, total bilirubin (all continuous variables) and
gender, antihyperglycemics, insulin, antihyperlipidemics, antihypertensives, type 2 diabetes mellitus (all categorical variables)
Model 3: Age, Glucose, total cholesterol, HDL-c, LDL-c, uric acid, creatinine, hsCRP, SBP, DBP, AST, total bilirubin (all continuous variables)
and gender, antihyperglycemics, insulin, antihyperlipidemics, antihypertensives, type 2 diabetes mellitus (all categorical variables)
Model 4: Age, Glucose, total cholesterol, HDL-c, LDL-c, ALT, uric acid, creatinine, hsCRP, SBP, DBP, AST, total bilirubin (all continuous
variables) and gender, antihyperglycemics, insulin, antihyperlipidemics, antihypertensives, type 2 diabetes mellitus (all categorical variables)
disease in men. The ROC-analysis-estimated clinical
accuracy of uric acid in men as a single parameter did
not show any significant discriminatory ability towards
fatty liver disease: AUC (95% CI) = 0.576 (0.500-
0.650), P>0.05. The calculated AUC for ALT and
uric acid in women as single parameters revealed that
only uric acid had a good clinical accuracy for fatty
liver development: AUC (95% CI) = 0.820 (0.779-
0.858), P<0.001 (Table VII).
Additionally, we constructed four models using
predictive probabilities generated by logistic
regression analysis. Figure 1 and Table VII showed
ROC curve for the Model 1 in men. The AUC of this
model was 0.932 indicated excellent discriminatory
capability towards fatty liver development. The same
was found for models 2, 3 and 4 generated in women
(Figure 2 and Table VII). All of them indicated
excellent discriminatory capability towards fatty liver
development. The pair-wise comparisons of ROC
curves between Models 2 and 4 (AUC difference
=0.006, P=0.073) and Models 3 and 4 (AUC=0.006,
P=0.061) showed that improvement with ALT and
uric acid together in the same model was not
statistically significant in discriminatory capability
towards fatty liver disease (data not presented). Also,
a pair-wise comparison of Model 2 and Model 3 ROC
curves (AUC difference=0.000, P=0.956) was not
significant in discriminating patients with and without
fatty liver disease. ALT in the Model 2 and uric acid in
the Model 3, both with the same other clinical
parameters could be considered to have the same
clinical accuracy for fatty liver disease development. 
Finally, ROC analysis was used to estimate cut-
off values for ALT in men and ALT and uric acid in
women in our study population associated with
increase in the prevalence of the fatty liver disease.
The cut-off value for ALT was 19 IU/L (AUC=0.746,
sensitivity 63%, specificity 72%, P<0.001) in women
and 22 IU/L (AUC = 0.804, sensitivity 61%,
specificity 95%, P<0.001) in men. The cut-off value
for uric acid was 274 mmol/L (AUC=0.821,
sensitivity 68%, specificity 82%, P<0.001) in women.
Discussion
The findings of the current study reveal that ALT
was independent predictor of the fatty liver disease as
determined by FLI in both men and women, whereas
serum uric acid was its independent predictor only in
women (Table VI). Moreover, unlike commonly used
threshold of 40 IU/L in clinical practice (12), we have
shown that lower cut-off levels of ALT activity in our
study population are associated with the increased
prevalence of the fatty liver disease. Namely, the cut-
off values in our study are as follows: ALT was 19
IU/L (AUC=0.746, sensitivity 63%, specificity 72%,
P<0.001) in women and 22 IU/L (AUC=0.804,
sensitivity 61%, specificity 95%, P<0.001) in men.
Our results are in line with some previous reports that
suggest the ALT cut-off level used in NAFLD
diagnosis should be downward in order to improve
the sensitivity of the method and to better identify
individuals being at risk of NAFLD, as well as to
prevent its progression (11, 12). Namely, Miyake et
al. (11) have reported ALT activity to be 17 IU/L for
females and 25 IU/L for males, as the cut-off levels
used for NAFLD diagnosis. Epidemiological studies
have also recommended lower cut-off levels (i.e., 19
IU/L for females and 30 IU/L for males) to be
accepted as a normal upper limit level (12).
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Figure 1 ROC curves for models’ discriminatory abilities
towards fatty liver disease in men.
Figure 2 ROC curves for models’ discriminatory abilities
towards fatty liver disease in women.
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However, despite suggested lower ALT cut-off
levels, there are studies that reject that ALT is a
reliable marker of NAFLD (8, 12, 13). In line with
this, van den Berg et al. (8) have shown that even
80.3% of individuals that were classified into the
group with NAFLD had normal ALT, when using the
upper limit of normal levels of this enzyme. Similarly,
another study has confirmed that normal ALT
activities were observed in 79% of subjects with
hepatic steatosis (24). Although ALT exists in two
isoforms in humans (25, 26), the ALT2 isoform
makes the main contribution to homeostasis of free
fatty acids (FFA), being highly expressed in adipose
tissue of obese individuals (25). In addition, increased
lipid peroxidation can cause the ALT to leak more
easily out of the hepatocytes. Moreover, it is assumed
that increased ALT activity in circulation may also be
a result of the compensatory response to the
impaired hepatic insulin signalling (25).
We failed to confirm the independent relation -
ship between uric acid and FLI in males, but con -
firmed only in females. In addition, the cut-off value
for uric acid was 274 mmol/L (AUC=0.821,
sensitivity 68%, specificity 82%, P<0.001) in women.
However, it is questionable whether hyperuricemia
raises the risk for fatty liver occurrence in females
more than in males since controversy exists in
literature concerning the relationship between serum
uric acid and NAFLD (14–17). A study conducted by
Wu et al. (15) in a large population group showed
that the relationship between uric acid and NAFLD
was significantly stronger in females than in males.
Similar observations were reported by Yang et al. (16)
in a four-year retrospective cohort study in Chinese
population. The independent effect of hyperuricemia
(i.e., defined as serum uric acid level level of
>360 mmol/L in females) on NAFLD was stronger in
females than in males, but it was found only in non-
obese subjects (16). To make this question more
complicated, Fan et al. (14) reported that an increase
in serum uric acid was independently associated with
the higher risk of NAFLD only in males, but not in
females in a study that encompassed exclusively
individuals with DM2. 
On the contrary, recent large meta-analysis
(17) has reported that increased risk for NAFLD
occurrence is significantly associated with hyper -
uricemia in both males and females. Moreover, uric
acid was found to directly inhibit insulin signalling and
induce insulin resistance, which is considered to be
the underlying mechanism of hepatic steatosis (14).
Importantly, Lanaspa et al. (27) reported that serum
uric acid could directly stimulate hepatic fat synthesis.
However, due to gender-difference observed in
relation with serum uric acid and hepatic steatosis in
many studies, it may be assumed that uric acid acts
on fatty liver development through different mecha -
nisms in males and females. Future studies are
needed to elucidate this assumption.
The main disadvantage of the current study is its
cross-sectional design, which does not allow making
a cause-effect inference. Moreover, we have not
evaluated hepatic steatosis directly by ultrasound,
computed tomography, or liver biopsy, but with FLI.
Nevertheless, we followed the 2016 EASL-EASD-
EASO NAFLD guidelines  recommendations on the
usage of the serum biomarkers as a preferred
diagnostic tool with the FLI as one of the best
validated steatosis scores for screening studies in
large population samples (22). The strength of the
current study, and advantage over our previous
studies (20, 21) is the fact that we included a large
sample size of population of Montenegro. Therefore,
we assume that lower cut-off levels of ALT in both
males and females, as well as serum uric acid levels
in females only, can be reliable predictors of FLI,
which can facilitate identifying individuals having a
great risk of fatty liver disease development.
Additional studies are needed to confirm our results,
as well as to make a comparison between these data
(i.e., fatty liver assessed with FLI algorithm) and fatty
liver as assessed with ultrasound in relation to ALT
and uric acid levels.
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